<DOC>
	<DOCNO>NCT00407225</DOCNO>
	<brief_summary>The purpose phase 2 study determine difluprednate ophthalmic emulsion effective treatment postoperative inflammation .</brief_summary>
	<brief_title>Study Difluprednate Ophthalmic Emulsion Treatment Postoperative Inflammation</brief_title>
	<detailed_description>The objective ass efficacy safety 0.002 % 0.05 % difluprednate ophthalmic emulsion patient postoperative inflammation cataract surgery ( implantation intraocular lens ) . In addition , evaluation system future dose-finding phase III study difluprednate ophthalmic emulsion establish .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Difluprednate</mesh_term>
	<mesh_term>Fluprednisolone</mesh_term>
	<criteria>Patients mean postoperative ( day surgery day surgery ) flare intensity 30 photon counts/msec Male female patient age 12 &lt; 75 year able accurately express symptom Patients provide write informed consent prior start study Inpatients ( patient allow discharged hospital study period ) Patients meet inclusion criterion Patients receive systemic administration , topical application head face ( include instillation eye ) steroid , nonsteroidal antiinflammatory drug , antiphlogistic enzyme , immunosuppressive drug colchicine within 1 week prior start study treatment Patients glaucoma ocular hypertension ( IOP : 21 mmHg ) Patients corneal abrasion ulcer Patients viral keratoconjunctival disease , tuberculosus eye disease , fungal eye disease bacterial eye disease Patients diabetes meet follow criterion HbA1C 9.0 % within 1 month prior obtain inform consent . Proliferative diabetic retinopathy present . Rubeosis iridis present . Patients allergy steroid Patients require use contact lens study period Women might pregnant Patients participate another clinical study within 6 month prior start present study Patients sensitive steroid ( patient previously experience increase IOP instillation steroid ) Patients Grade 5 nuclear hardness diagnose accord EmeryLittle classification Patients fibrins posterior rupture baseline ( F0 )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>